The Role of the Innate Immune System in the Pathogenesis of Type 1 Diabetes
UpcomingNational Institutes of Health · Opportunity number RFA-AI-28-029 · Forecast
Eligibility
Nonprofits are listed as eligible applicants.
- County governments
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Native American tribal organizations (other than Federally recognized tribal governments)
- Small businesses
- City or township governments
- Public and state controlled institutions of higher education
- For profit organizations other than small businesses
- Special district governments
- Independent school districts
- Public housing authorities/Indian housing authorities
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- State governments
- Native American tribal governments (Federally recognized)
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Description
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance the National Institutes of Health (NIH) mission by utilizing Special Statutory Funding Program for Type 1 Diabetes Research funds to support studies focused on the involvement of the innate immune system in the initiation of Type 1 diabetes (T1D). This initiative directly aligns with the first goal of the congressionally mandated Special Diabetes Program, which is to identify the genetic and environmental causes of T1D. By engaging multidisciplinary teams with expertise in innate immunity and beta-cell biology, the program aims to elucidate how innate immune components interact with pancreatic tissues and beta cells. The program will leverage the use of new approach methodologies (NAMs) to precisely define the timing and impact of environmental perturbations that activate innate immune pathways. Ultimately, these studies may enable earlier identification of individuals at elevated risk for T1D (beyond genetic susceptibility) and lay the groundwork for future prevention and therapeutic strategies. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
Funding
| Total program funding | $15,000,000 |
|---|---|
| Award floor | Not listed |
| Award ceiling | Not listed |
| Category | Health |
| Assistance listing | 93.855 |
Official sources
Last verified on Grants.gov Nov 4, 2026. Grantvello is not affiliated with Grants.gov or National Institutes of Health. The notice on Grants.gov is the binding text.